Chinese Journal of Magnetic Resonance ›› 2015, Vol. 32 ›› Issue (2): 273-282.doi: 10.11938/cjmr20150210

Previous Articles     Next Articles

A Biocompatible Gadolinium (III)-Poly (Aspartic Acid-Co-Phenylalanine) for Liver Magnetic Resonance Imaging Contrast Agent

XIAO Yan1,ZHAN You-yang1,XUE Rong1,LI Xiao-jing1*,PEI Feng-kui1,FENG Jiang-hua2*,ZHAN Bo-han2   

  1. 1. Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022;
    2. Department of Electronic Science, Xiamen University, Xiamen 361005
  • Received:2015-01-30 Revised:2015-05-19 Online:2015-06-05 Published:2015-06-05
  • About author:XIAO Yan(1984-), female, born in Hebei province, PhD., specializing in MRI contrast. *Corresponding author:LI Xiao-jing, Tel: +86-431-85262219, E-mail: xjli@ciac.ac.cn; FENG Jiang-hua, Tel: +86-592-2183301, E-mail: jianghua.feng@xmu.edu.cn.
  • Supported by:

    The National Natural Science Foundation of China (20975097 and 21305134).

Abstract:

A new biocompatible gadolinium (III)-macromolecule (AP-EDA-DOTA-Gd) was developed as a magnetic resonance imaging (MRI) contrast agent. Poly (aspartic acid-cophenylalanine) was synthesized, modified via ethylenediamine, conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and finally chelated gadolinium (III), yielding gadolinium (III)-based macromolecule (AP-EDA-DOTA-Gd). The hemolytic tests showed the hemocompatibility of this gadolinium (III)-based macromolecular conjugate. In vitro, AP-EDA-DOTA-Gd could be degraded, when it was incubated with cathepsin B in phosphate buffered solution (pH = 5.5). The T1-relaxivity (15.95 mmol–1·L·s–1) of AP-EDA-DOTA-Gd was 2.9 times of that (5.59 mmol–1·L·s–1) of the clinical MRI contrast agent (Gd-DOTA) at 1.5 T and 25 ℃. The liver enhancement of AP-EDA-DOTA-Gd was 63.5±6.1% during the maximum enhancement time (50-80 min), which was much better than that of Gd-DOTA (24.2±2.9%, 10-30 min). AP-EDA-DOTA-Gd was expected to be a potential liver MRI contrast agent.

Key words: MRI contrast agent, gadolinium (III)-macromolecule, liver, relaxivity

CLC Number: